Introduction. The change from risk-factor-based to nearly comprehensive screening of gestational diabetes (GDM) identifies more but milder cases of the disease. The main aim of this study was to evaluate the effect of this screening policy change on neonatal outcomes and care. Material and methods. A population-based register study in Finland. GDM cases during risk-factorbased (year 2006, n = 5179) and comprehensive (2010, n = 6679) screenings were identified through the Medical Birth Register. All singletons without maternal GDM or prepregnancy diabetes served as controls (n = 51 746 and n = 52 386, respectively). The main outcomes were macrosomia, neonatal hypoglycemia and the need for care in a neonatal ward. Results. In the GDM group, the mean birthweight decreased between the study years from 3660 g to 3595 g and the prevalence of macrosomia from 5.6 to 4.1% even after adjustment for maternal age, parity and prepregnancy body mass index. The adjusted mean difference in birthweight between GDM and control newborns decreased from 70 to 22 g between the study years. The prevalence of neonatal hypoglycemia increased from 18.0 to 22.1% in the GDM group. However, neonatal hypoglycemia was more often treated without care in a neonatal ward. The proportion of infants treated on a neonatal ward decreased in both the GDM and control groups between the study years. Conclusions. In newborns, comprehensive GDM screening led to decreased mean birthweight and macrosomia rates, but the prevalence of neonatal hypoglycemia increased. This places substantial demands for delivery hospitals and healthcare resources.
Introduction
Gestational diabetes mellitus (GDM), defined as an abnormal glucose metabolism with onset or first recognition during pregnancy, is associated with an increased risk of perinatal complications and neonatal morbidities such as hypoxia, hypoglycemia, hyperbilirubinemia and birth trauma due to macrosomia (1) (2) (3) (4) (5) (6) . In the long term, prenatal exposure to maternal GDM increases the risk of overweight and of metabolic syndrome in the offspring during childhood and adolescence (7) (8) (9) (10) (11) (12) (13) .
GDM is common. Using the uniform diagnostic criteria of the International Association of the Diabetes and Pregnancy Study Group based on the Hyperglycemia and Adverse Pregnancy Outcome study, its prevalence varies from 9.3 to 25.5% in different populations (14) . The reason for this large variation in frequency is unclear, but it may partly depend on genetic susceptibility and obesity. It is important to diagnose GDM because its effective treatment reduces perinatal complications and may also improve the offspring's long-term outcomes (7, (15) (16) (17) (18) .
In Finland, new national screening and diagnostic guidelines for GDM were launched in 2008. The previously used risk-factor-based screening was replaced with nearly comprehensive screening, excluding only the estimated approximately 20% of women at very low risk of GDM. The shift to wide-scale screening led to a significant increase in women with mainly diet-treated GDM, who were more often primiparous and had a lower body mass index (BMI) (19) . Our aim was to evaluate how this change of policy affected the perinatal outcome and the need for care on a neonatal ward.
Material and methods

Medical Birth Register
Our data are based on the Finnish Medical Birth Register (MBR), which was initiated in 1987 and reformed in 2004 to improve its reliability. The MBR contains data on all mothers with live births or stillbirths with a gestational age ≥ 22 weeks or a birthweight ≥ 500 g. For each delivery in Finland, a structured form for the MBR is completed by the delivery hospital within 7 days of delivery, including data regarding the course and complications of the pregnancy and the delivery, as well as information related to the perinatal health of the newborn, such as birthweight and length, Apgar score, cord blood pH, treatments and diagnosis with International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) codes until the 7th day after birth. The register is completed using data compiled by the Population Register Center on live births and by Statistics Finland regarding stillbirths and infant deaths. The data quality of the MBR has been shown to be high for most of the applicable variables (20, 21) .
Definition of GDM
Since 2004, the MBR has also included information on whether the oral glucose tolerance test (OGTT) was performed to diagnose GDM, whether the result was abnormal and whether insulin treatment was initiated. For the present study, mothers were identified through the MBR using these OGTT data.
A diagnosis of GDM was applied if a woman had an abnormal OGTT result or insulin therapy was initiated during pregnancy according to the MBR. After the exclusion of multiple births, mothers with prepregnancy type 1 or type 2 diabetes (ICD-10 codes O24.0 or O24.1) and preterm delivery (<37 weeks of gestation) of neonates with abnormally high birthweight standard deviation (>3 SD) scores (birthweight standardized for the length of gestation), which are likely to reflect erroneous recordings, 5179 ( 
Screening for GDM
In 2008, new national guidelines to screen and diagnose GDM were launched in Finland. Risk-factor-based screening was replaced by nearly comprehensive screening (Table 1) . According to both screening policies, both the screening and diagnosis of GDM were carried out through a standard 2-h 75-g OGTT, which was mainly performed between 24 and 28 weeks of gestation. For both years, the OGTT was recommended between 12 and 16 weeks of gestation for high-risk groups (before 2008, prior GDM; from 2008 onwards, prior GDM, BMI ≥35 or polycystic ovary syndrome with insulin resistance), and if the result was normal, the OGTT would be repeated between 24 and 28 weeks of gestation. In the OGTT, blood glucose concentrations are measured after an overnight fast. Venous plasma glucose equal to or higher than 5.3, 10.0 and 8.6 mmol/L at fasting and 1 and 2 h after the glucose dose, respectively, was diagnostic during both years. In both periods, a diagnosis of GDM was applied when at least one abnormal value was present in the OGTT. After the diagnosis of GDM, the patients received dietary and lifestyle counseling and began the self-monitoring of plasma glucose concentrations. According to the treatment guidelines at the
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Comprehensive screening of gestational diabetes mellitus led to decreased mean birthweight and macrosomia rates, but the prevalence of neonatal hypoglycemia increased. 
Outcome
Gestational age was based on the best estimate of the duration of pregnancy at delivery. During these years, systematic ultrasound examination to determine gestational age was offered to all pregnant women between 10 +0 and 13 +6 weeks of gestation, and detailed examination of fetal anatomy was offered between 19 +0 and 22 +0 weeks of gestation. The MBR data include the weight of the newborn in grams and the length in full centimeters. The ponderal index, representing the body constitution of the newborn, was calculated using weight/length 3 (kg/m 3 ). Macrosomia was defined as being large for gestational age (LGA), as indicated by a birthweight that was +2 SD from a reference value (22) .
Regarding neonatal outcomes, umbilical cord artery pH, asphyxia, Apgar score and the need and indication for treatment on a neonatal ward were reported. The six most frequent neonatal diagnoses, according to the ICD-10 codes set by a pediatrician, were used to evaluate neonatal morbidity. Those diagnoses were hypoglycemia (P70.0-70.9), hyperbilirubinemia (P59.0-59.9), neonatal respiratory distress syndrome (P22.0), transient tachypnea of the newborn (P22.1), fracture of the clavicle (P13.4) and Erb's and Klumpke's palsy (P14.0; P14.1). The Current Care Guidelines recommend repeated plasma glucose measurements for all newborns of women with GDM -for nonsymptomatic infants usually six measurements during the first 48 h and for symptomatic infants more frequently. Intravenous glucose is recommended (a) if a single measurement ≤ 1.4 mmol/L or; (b) if a single measurement is 1.5-2.5 mmol/L and a repeated measurement after supplementary feeding is ≤2.5 mmol/L. There is no clear definition of neonatal hypoglycemia; in our experience these diagnostic codes where set when the neonate received intravenous glucose (23) .
Perinatal mortality was defined as the combined rate of stillbirth and early neonatal mortality within the first 7 days of life. The time for hospital treatment in days and the location of the newborn at the seventh day after birth (at home, in a neonatal ward, in a maternal ward with mother or in another hospital) was recorded.
This study was approved by the regional Ethics Committee in the Northern Ostrobothnia Hospital District, Number 2008/43, date of approval 19 June 2008.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics versions 21 and 22 (IBM Corp., Armonk, NY, USA). The differences between the study groups were compared by using Pearson's chi-squared test or an independent sample t-test. Values of p < 0.05 are regarded as statistically significant. Logistic regression analyses were performed to estimate the odds ratios and 95% CIs for the risk of outcomes consequent upon GDM in different study periods. Mean differences with 95% CI were calculated using linear regression. We present unadjusted regression analyses and those adjusted for maternal age, parity and prepregnancy BMI. We also report the results after further adjusting for maternal occupational status and smoking during pregnancy. Interactions were tested by adding the product term between the two variables of interest into the regression model.
Results
During the risk factor-based screening in 2006, 15 682 women (27.5% of all parturients) underwent OGTT and 5179 (9.1%) were diagnosed with GDM. The corresponding rates in 2010 were 30 365 (51.4%) and 6679 (11.3%), respectively ( Table 2 , and see, Figure S1 ). Unexpectedly, both the absolute number and the proportion of insulintreated women with GDM decreased significantly (Table 3) . Both the mean birthweight and the rate of LGA decreased among newborns of women with GDM after the implementation of comprehensive screening [65 g from 3660 (SD 542) to 3595 g (SD 561) and from 5.6 to 4.1%; adjusted ORs 1.81 and 1.46, respectively (see Table S1 )]. In the GDM group, both the ponderal index and the absolute number of LGA cases decreased between the study years ( Table 2 ). In the control group, there was a smaller decrease in birthweight and birthweight SD score ( Table 2 ). The birthweight difference between the GDM and control groups decreased from 70 to 22 g between the study years when adjusted for maternal age, prepregnancy BMI, and parity (SD scores of 0.20 and 0.11, respectively; see, Table S1 ).
Newborns in the GDM group were born earlier than those in the control group during both study years. The difference in gestational age increased between the GDM and control groups from 0.18 to 0.25 weeks between the study years ( Table 2) . Newborns of women with GDM were 1.7-fold more likely to require care in a neonatal ward than controls during both study years (see , Table S1 ). The need for care on a neonatal ward decreased in both the GDM and control groups although the absolute number of GDM group newborns did not change substantially. Table 2 shows the incidence of neonatal conditions, whereas the Supplementary material (Table S1) shows the adjusted and unadjusted odds ratios for these outcomes. The incidence of neonatal hypoglycemia clearly increased in the GDM group (18.0% vs. 22.1%) after the new screening policy was introduced (Tables 2, 3 and see, Table S1 ). However, it was the most common indication for care on a neonatal ward during both study years (Tables 2 and 3) but was less often treated on a neonatal ward during comprehensive screening (see , Table S2 ). Transient tachypnea was more common in infants of women with GDM, but the rates of respiratory distress syndrome did not differ between the study groups. These odds ratios were similar during both study periods, and they were attenuated after adjustment. The higher incidence of fractures of the clavicle seen in the GDM group disappeared after comprehensive screening, but Erb's palsy was more common in infants of women with GDM during both study years. Perinatal mortality rates did not differ in the GDM and control groups between the study years ( Table 2) .
In addition to the adjustment for maternal age, parity and prepregnancy BMI shown in the Supplementary material (Table S1) , we further adjusted for maternal occupational status and smoking during pregnancy for most of the neonatal outcomes. This adjustment did not alter the results.
The body size and LGA rate of infants of diet-treated mothers decreased significantly from the risk-factor-based to the comprehensive screening period. This change was not seen among infants of insulin-treated mothers -the ponderal index of their offspring was higher during comprehensive screening. They were also more likely to be admitted to a neonatal ward, but the difference to offspring of diet-treated mothers narrowed between the study periods. The most common indication for care on a neonatal ward with both diet-treated and insulin-treated mothers was neonatal hypoglycemia (Table 3 , see, Table S2 ).
Discussion
We showed previously that the introduction of a largescale screening policy for gestational diabetes led to a significant increase in the proportion of women with GDM, who mainly had a mild form of the disease (19) . In the present study, we further found that in newborns, screening policy change led to decreased mean birthweight and macrosomia rates, but the prevalence of neonatal hypoglycemia increased in both diet-and insulin-treated mothers. However, this was not accompanied by an increase in care on a neonatal ward. The need for care on a neonatal ward did not grow to the same degree as the prevalence of GDM, which may be due to the increased proportion of mild forms of disease. The amount of insulin-treated women with GDM decreased significantly when the new uniform guidelines standardized both screening policy and cut-off levels to insulin treatment (19) . However, the effect of this change to the increased incidence of neonatal hypoglycemia is unclear. Detailed new guidelines may also have encouraged a more intensive neonatal hypoglycemia screening policy in which all newborns of GDM mothers were monitored regardless of the symptoms, leading to increased hypoglycemia rates. However, the proportion of hypoglycemia as a primary indication for care on a neonatal ward did not increase, which indicates that low blood glucose concentration was mainly treated on a maternity ward with intensified oral feedings; administration of intravenous glucose generally requires treatment on a neonatal ward. The monitoring of neonatal hypoglycemia, however, places substantial demands on nursing staff and it might be worth considering whether systematic monitoring to this extent is necessary. Therefore, we agree with the conclusion of the Atlantic Diabetes in Pregnancy study arguing that the new comprehensive screening requires a great deal of manpower and resources, although it provides an opportunity to reduce the morbidity of the mother and infant (24) .
Infants of women with GDM are known to require care on a neonatal ward more often than infants of women without GDM (5, 24) , which was also seen in the present study. To some extent, the threshold for follow up on a neonatal ward may be lower in GDM cases than in controls; it may also vary between hospitals. In the present study, in-ward treatment decreased to the same degree in both the GDM and control groups, which may reflect a common trend of supporting rooming-in instead of separating the mother from her newborn. In addition, optimal GDM treatment is known to decrease the risk of severe neonatal morbidity (15) . Although the proportion of infants treated in a neonatal ward decreased, their absolute number remained nearly the same because of an increased number of GDM pregnancies.
During comprehensive screening, infants born to women with GDM had lower birthweight and birthweight SD and were less likely to be macrosomic compared with risk-factor-based screening. The decrease was accompanied by a lower rate of clavicle fracture. However, the decrease of macrosomia was limited to the diet-treated group, also after adjustment for maternal age, parity and prepregnancy BMI. There are two possible explanations for this decrease. First, comprehensive screening possibly identifies milder cases, and therefore, macrosomia is less probable. Another explanation is that the reduction is a result of uniform counseling and follow up based on the new Current Guidelines. Indeed, treatment of mild GDM has been shown to reduce the risk of macrosomia (15, 17) .
The strength of our study is that it included a large, unselected study population based on comprehensive national register data. In Finland, virtually all pregnant women receive maternal health care free of charge and give birth in a public hospital. Therefore, systematic and unselected data acquisition is possible. The coverage of the Finnish MBR is practically complete, and most variables are of high quality. Because of the study design, however, we did not have data on the women's previous pregnancies; therefore, we were unable to estimate the exact proportion of very-low-risk women for whom the new guidelines do not recommend OGTT, or to evaluate the significance of specific GDM risk factors during different study periods.
In conclusion, comprehensive GDM screening detects more cases of GDM, but these are less severe. This is also reflected in the neonatal outcomes: during comprehensive screening, infants of women with GDM were smaller, less often macrosomic and required care in a neonatal ward less often. Although the proportion of infants treated on a neonatal ward did not increase in the same relation with the total GDM cases, the increased prevalence of GDM and neonatal hypoglycemia placed substantial demands on the nursing staff and the delivery hospitals.
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